Skip to main content

RBC Capital Keeps Their Buy Rating on Legend Biotech (LEGN)

Tipranks - Tipranks - Fri Dec 12, 2025

In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on Legend Biotech, with a price target of $74.00.

Claim 50% Off TipRanks Premium and Invest with Confidence

According to TipRanks, Timashev is a 5-star analyst with an average return of 30.9% and a 57.92% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Exelixis, and Legend Biotech.

In addition to RBC Capital, Legend Biotech also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued yesterday. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Legend Biotech (NASDAQ: LEGN).

See the top stocks recommended by analysts >>

Based on Legend Biotech’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $272.33 million and a GAAP net loss of $39.69 million. In comparison, last year the company earned a revenue of $160.21 million and had a GAAP net loss of $125.32 million

Read More on LEGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).